We have a suspicion that you are an automated web bot software, not a real user. To keep our site fast for other users, we have slowed down this page. The slowdown will gradually disappear. If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu. Also note that all data for hgGeneGraph can be obtained through our public MySQL server and all our software source code is available and can be installed locally onto your own computer. If you are unsure how to use these resources, do not hesitate to contact us.
UCSC Genome Browser Gene Interaction Graph
Gene interactions and pathways from curated databases and text-mining

◀ Back to MTOR

BCL2 — MTOR

Text-mined interactions from Literome

Asnaghi et al., Oncogene 2004 : Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt
Tirado et al., Oncogene 2005 : Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity
Kasper et al., Curr Opin Oncol 2007 (Sarcoma) : Included are recent developments in targeted therapy, focusing on the following : antiangiogenic and immunomodulatory drugs ( e.g. anti-cytotoxic T lymphocyte associated antigen-4 monoclonal antibody ), Bcl-2 antisense therapy, raf kinase and mammalian target of rapamycin inhibition , heat shock protein modulators, minor groove binders and other agents being developed
Kasper et al., Rev Recent Clin Trials 2007 (Sarcoma) : Moreover, we give an overview on the emerging compounds for patients with soft tissue sarcoma including recent developments of targeted therapy focusing on antiangiogenic and immunomodulatory drugs, Bcl-2 antisense therapy, raf kinase and mTOR inhibition , minor groove binders, and other agents being developed
Ramanathan et al., Proc Natl Acad Sci U S A 2009 : Bcl-xl, but not VDAC1, is a kinase substrate for mTOR in vitro, and mTOR regulates the association of Bcl-xl with mTOR
Guo et al., Zhonghua Xue Ye Xue Za Zhi 2012 (Precursor Cell Lymphoblastic Leukemia-Lymphoma) : Oridonin inhibited activation of ABL kinase and its downstream Akt/mTOR , Raf/MEK/ERK and STAT5 signaling pathways, which were constitutively activated in SUP-B15 cell line, down-regulated the level of anti- apoptotic protein Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax
Rahmani et al., Cancer Res 2013 (Leukemia, Myeloid) : PI3K/mTOR inhibitors markedly downregulated Mcl-1 but increased Bim binding to Bcl-2/Bcl-xL ; the latter effect was abrogated by ABT-737 ... PI3K/mTOR inhibitors markedly downregulated Mcl-1 but increased Bim binding to Bcl-2/Bcl-xL ; the latter effect was abrogated by ABT-737